Edition:
United States

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

10.25USD
26 May 2017
Change (% chg)

$-0.25 (-2.38%)
Prev Close
$10.50
Open
$10.40
Day's High
$10.40
Day's Low
$10.25
Volume
142,032
Avg. Vol
214,783
52-wk High
$17.50
52-wk Low
$9.30

Latest Key Developments (Source: Significant Developments)

Sucampo Q1 gaap earnings per share $0.10
Wednesday, 3 May 2017 06:30am EDT 

May 3 (Reuters) - Sucampo Pharmaceuticals Inc ::Sucampo reports first quarter 2017 financial results.Q1 gaap earnings per share $0.10.Q1 revenue $56.3 million versus i/b/e/s view $54.1 million.Sees fy 2017 adjusted earnings per share $1.00 to $1.10.Q1 adjusted earnings per share $0.23.Sees fy 2017 revenue $220 million to $230 million.Q1 earnings per share view $0.27 -- Thomson Reuters I/B/E/S.Says company reiterates 2017 guidance.Fy2017 earnings per share view $1.09, revenue view $233.4 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo acquires Vtesse in a deal valued at $200 mln
Monday, 3 Apr 2017 06:30am EDT 

Sucampo Pharmaceuticals Inc : Sucampo Pharmaceuticals Inc- transaction valued at $200 million upfront . Sucampo acquires Vtesse Inc . Deal expected to be accretive to earnings beginning in 2019 . Sucampo Pharmaceuticals Inc- Vtesse employees are expected to join Sucampo . Sucampo pharmaceuticals - acquisition provides sucampo with vts-270, which is in a pivotal study for treatment of niemann-pick disease type c1 (npc-1) . Vtesse team will continue to support advancement of vts-270 . Sucampo Pharma -upfront payment made in form of issuance of 2.8 million Sucampo class a common shares to Vtesse shareholders and $170 million in cash on hand . Sucampo Pharmaceuticals Inc- revised full year 2017 guidance post Vtesse, revenue $220 million - $230 million . Sucampo pharmaceuticals inc- revised full year 2017 guidance post Vtesse for adjusted. Eps $1.00 - $1.10 . Sucampo Pharmaceuticals - Vtesse and Sucampo intend to establish a foundation after closing of acquisition to support research related to NPC disease .Sucampo Pharmaceuticals Inc says revised full year 2017 guidance guidance post Vtesse, free cash flow $86 million - $96 million.  Full Article

Sucampo reports Q4 EPS $0.34
Wednesday, 8 Mar 2017 06:30am EST 

Sucampo Pharmaceuticals Inc - : Sucampo reports fourth quarter and full year 2016 financial results . Q4 adjusted earnings per share $0.68 . Q4 gaap earnings per share $0.34 . Q4 revenue $73 million versus I/B/E/S view $66 million . Q4 earnings per share view $0.48 -- Thomson Reuters I/B/E/S . Sees fy 2017 adjusted earnings per share $1.35 to $1.50 . Sees fy 2017 revenue $220 million to $230 million . Reiterated its guidance for full year ending December 31, 2017 . Fy2017 earnings per share view $1.60, revenue view $228.2 million -- Thomson Reuters I/B/E/S .Andrew Smith, chief financial officer, will be leaving co; Peter Pfreundschuh, will become new CFO effective on March 20.  Full Article

Sucampo Pharmaceuticals say issued $300 mln of convertible senior notes due 2021 - SEC filing
Tuesday, 27 Dec 2016 04:34pm EST 

Sucampo Pharmaceuticals Inc : Sucampo Pharmaceuticals Inc - notes were issued to Leerink Partners LLC . Sucampo Pharmaceuticals - on Dec 27, 2016, co issued $300.0 million aggregate principal amount of its 3.25 pct convertible senior notes due 2021 - SEC filing .Sucampo Pharmaceuticals - to use net proceeds from note offering to repay in full approximately $238.4 million due under co's senior secured credit facility.  Full Article

Sucampo Q3 adjusted EPS $0.28
Wednesday, 9 Nov 2016 06:30am EST 

Sucampo Pharmaceuticals Inc : Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance . Sucampo pharmaceuticals inc - announces settlement with dr. Reddy's laboratories for amitiza . Sees 2016 total revenue $220.0 million to $225.0 million . Fy2016 earnings per share view $1.03, revenue view $205.7 million -- Thomson Reuters I/B/E/S . Sees 2016 adjusted ebitda $110.0 million to $115.0 million . Sucampo pharmaceuticals - phase 3 trial of amitiza in pediatric functional constipation in children 6-17 yrs of age did not achieve primary endpoint . Sucampo pharmaceuticals inc- completed a settlement and license agreement with dr. Reddy's laboratories, ltd. And certain of its affiliates . Sucampo pharmaceuticals - agreement resolves patent litigation in united states related to sucampo's amitiza 8 mcg and 24 mcg soft gelatin capsules . Sucampo pharmaceuticals - agreement provides for an entry date more than six years from wednesday and profit sharing on product sales by dr. Reddy's . Sucampo reports third quarter 2016 financial results . Q3 adjusted earnings per share $0.28 . Q3 gaap earnings per share $0.19 . Q3 revenue $57.9 million versus i/b/e/s view $51.4 million . Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S .Sees fy 2016 adjusted earnings per share $1.20 to $1.25.  Full Article

Sucampo reports Q2 GAAP loss per share $0.02
Wednesday, 3 Aug 2016 06:30am EDT 

Sucampo Pharmaceuticals Inc : Q2 GAAP loss per share $0.02 . Q2 adjusted earnings per share $0.23 . Q2 earnings per share view $0.22 -- Thomson Reuters I/B/E/S . Q2 revenue $52 million versus I/B/E/S view $48.6 million . Sees FY 2016 adjusted earnings per share $0.97 to $1.07 . Sees FY 2016 revenue $195 million to $205 million .FY2016 earnings per share view $1.01, revenue view $203.6 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo Pharmaceuticals Inc reports top-line data from phase 2a study of cobiprostone
Tuesday, 19 Apr 2016 07:00am EDT 

Sucampo Pharmaceuticals Inc:Reports top-line data from phase 2a study of cobiprostone in patients with PPI-refractory non-erosive reflux disease and symptomatic gastroesophageal reflux disease.Says trial did not meet its primary endpoints.Says intends to discontinue development of cobiprostone for PPI-refractory NERD/sGERD.  Full Article

Sucampo Pharmaceuticals Inc reiterates FY 2016 guidance
Tuesday, 8 Mar 2016 06:30am EST 

Sucampo Pharmaceuticals Inc:Reiterated its earnings guidance for FY 2016.Expects total revenue of $195.0 million to $205.0 million, adjusted net income of $45.0 million to $50.0 million, adjusted EPS of $0.97 to $1.07, and adjusted EBITDA of $100.0 million to $105.0 million.Says adjusted net income guidance excludes amortization of acquired intangibles of about $17.6 million and amortization of the remaining inventory step-up costs of about $8.9 million.  Full Article

Sucampo Pharmaceuticals Inc enters into exclusive collaboration deal with cancer prevention pharmaceuticals
Monday, 11 Jan 2016 06:45am EST 

Sucampo Pharmaceuticals Inc:Press release - Sucampo enters into exclusive option and collaboration agreement with cancer prevention pharmaceuticals for development of late-stage cpp-1x/sulindac combination for familial adenomatous polyposis.Says phase 3 study expected to be complete in 2018.Says under the terms of the agreement, Sucampo will invest $5.0 million in cpp in the form of a convertible note.Says in addition, Sucampo will pay cpp an option fee of up to $7.5 million, payable in two tranches.Says under terms of the license, Sucampo and cpp would share equally in profits from the sale of approved products.Sucampo pharmaceuticals-co would acquire an exclusive license to product and would be obligated to pay cpp an aggregate of $190 million.  Full Article

Sucampo Pharmaceuticals Inc confirms FY 2016 guidance
Thursday, 7 Jan 2016 07:00am EST 

Sucampo Pharmaceuticals Inc:Confirms its previous guidance for FY 2016 of total revenue of $195.0 million to $205.0 million, adjusted net income of $45.0 million to $50.0 million, adjusted EPS of $0.97 to $1.07, and adjusted EBITDA of $100.0 million to $105.0 million.Says adjusted net income guidance excludes amortization of acquired intangibles of about $17.6 million and amortization of the remaining inventory step-up costs of about $8.9 million.  Full Article

More From Around the Web